M. Kraus Co Lowers stake in Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific (TMO) : M. Kraus Co reduced its stake in Thermo Fisher Scientific by 5.6% during the most recent quarter end. The investment management company now holds a total of 39,313 shares of Thermo Fisher Scientific which is valued at $5,713,751 after selling 2,330 shares in Thermo Fisher Scientific , the firm said in a disclosure report filed with the SEC on Apr 15, 2016.Thermo Fisher Scientific makes up approximately 3.93% of M. Kraus Co’s portfolio.

Thermo Fisher Scientific opened for trading at $146.12 and hit $147.77 on the upside on Wednesday, eventually ending the session at $147.35, with a gain of 0.62% or 0.91 points. The heightened volatility saw the trading volume jump to 13,29,224 shares. Company has a market cap of $58,389 M.

Other Hedge Funds, Including , Clean Yield Group reduced its stake in TMO by selling 855 shares or 13.55% in the most recent quarter. The Hedge Fund company now holds 5,453 shares of TMO which is valued at $792,539. Thermo Fisher Scientific makes up approx 0.35% of Clean Yield Group’s portfolio.Sit Investment Associates Inc reduced its stake in TMO by selling 500 shares or 1.01% in the most recent quarter. The Hedge Fund company now holds 48,955 shares of TMO which is valued at $7,115,120. Thermo Fisher Scientific makes up approx 0.13% of Sit Investment Associates Inc’s portfolio.Bremer Trust National Association reduced its stake in TMO by selling 1,108 shares or 4.0% in the most recent quarter. The Hedge Fund company now holds 26,597 shares of TMO which is valued at $3,865,608. Thermo Fisher Scientific makes up approx 1.10% of Bremer Trust National Association’s portfolio.Proficio Capital Partners boosted its stake in TMO in the latest quarter, The investment management firm added 265 additional shares and now holds a total of 332 shares of Thermo Fisher Scientific which is valued at $47,031. Thermo Fisher Scientific makes up approx 0.04% of Proficio Capital Partners’s portfolio.

On the company’s financial health, Thermo Fisher Scientific reported $2.12 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jan 28, 2016. Analyst had a consensus of $2.11. The company had revenue of $4652.50 million for the quarter, compared to analysts expectations of $4551.79 million. The company’s revenue was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.99 EPS.

Many Wall Street Analysts have commented on Thermo Fisher Scientific. Company shares were Reiterated by Mizuho on Apr 4, 2016 to “Buy”, Firm has raised the Price Target to $ 160 from a previous price target of $150 .Company shares were Reiterated by Topeka Capital Markets on Mar 2, 2016 to “Buy”, Firm has raised the Price Target to $ 155 from a previous price target of $145 .

Thermo Fisher Scientific Inc. is a provider of analytical instruments equipment reagents and consumables software and services for research manufacturing analysis discovery and diagnostics. The company operates through four segments: Life Sciences Solutions provides reagents instruments and consumables used in biological and medical research discovery and production of new drugs and vaccines as well as diagnosis of disease; Analytical Instruments provides instruments consumables software and services that are used in the laboratory; Specialty Diagnostics offers diagnostic test kits reagents culture media instruments and associated products and Laboratory Products and Services offers self-manufactured and sourced products for the laboratory.

Leave a Reply

Thermo Fisher Scientific - Is it time to Sell?

Top Brokerage Firms are advising their investors on Thermo Fisher Scientific. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.